J Korean Med Assoc.  2013 Dec;56(12):1091-1103. 10.5124/jkma.2013.56.12.1091.

Antivenom for snake bite in Korea

• Lim H
• Kang HG
• Kim KH

• KMID: 1783724
• DOI: http://doi.org/10.5124/jkma.2013.56.12.1091

Abstract

In Korea, there are four types of snakes, Glyoidius brevicaudus, G. intermedius (formerly named, saxatilis), G. ussuriensis, Rhabdophis tigrinus. The case-fatality rate in snake bite envenomation is very low. Snake venom is a heterogeneous mixture of pharmacologically active enzymatic, non-enzymatic protein, peptide toxins, other organic and inorganic substances. The pathophysiology evokes a complex series of events that depend on the combined and synergistic action of toxic and non-toxic components. The manifestation includes local and systemic effects. Local tissue effects includes of tissue pain, redness, swelling, tenderness, bullae formation, and necrosis. The major systemic manifestations of snake bite include neurotoxicity, myotoxicity, cytotoxicity, hemolytic, procoagulant, hemorrhagic, and hypotensive effects and interfere in platelet function. General care includes parenteral analgesia, antivenom administration, and serial assessments of limb swelling and laboratory tests. Despite the presence of soft tissue inflammation, prophylactic antibiotics are rarely required, and most patients achieve good outcomes with supportive care and antivenom alone. In the case of mild poisoning do not need to be treated with antivenom. In moderate to severe envenomation, antivenom should be administered. When administered antivenom, adverse reactions are monitored closely and treated early with epinephrine and anti-histamine. In future, we should establish algorithm provides guidance about clinical and laboratory observations, indications for and dosing of antivenom, adjunctive therapies, post-stabilization care, and management of complications from envenomation and therapy.

Keyword

Snake bites; Venoms; Antivenom

MeSH Terms

Analgesia
Anti-Bacterial Agents
Blood Platelets
Epinephrine
Extremities
Humans
Inflammation
Korea*
Necrosis
Nociceptive Pain
Poisoning
Snake Bites*
Snake Venoms
Snakes*
Venoms
Anti-Bacterial Agents
Epinephrine
Snake Venoms
Venoms

Reference

1. World Health Organization. Venomous snakes distribution and species risk categories [Internet]. Geneva: World Health Organization;cited 2013 Oct 20. Available from: http://apps.who.int/bloodproducts/snakeantivenoms/database/default.htm.

2. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioli L, Lalloo DG, de Silva HJ. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008; 5:e218.

3. National Health Insurance. National health insurance statistical yearbook 2011 [Internet]. Seoul: National Health Insurance;2012. cite 2013 Nov 12. Available from: http://www.nhic.or.kr/cms/board/board/Board.jsp?searchType=ALL&searchWord=&list_start_date=&list_end_date=&pageSize=&branch_id=&branch_child_id=&communityKey=B0075&pageNum=1&list_show_answer=N&boardId=20030&act=VIEW.

4. Shim JH, Son YJ, Lee SS, Park KS, Oh HB, Park YD. Ecological study on poisonous snake and investigation of the venom characteristics, snakebiting frequency in Korea. Korean J Environ Ecol. 1998; 12:58–77.

5. World Health Organization. Snake antivenom immunoglobulins [Internet]. Geneva: World Health Organization;cited 2013 Oct 20. Available from: http://who.int/bloodproducts/snake_antivenoms/en/.

6. Weinstein SA, White J, Keyler DE, Warrell DA. Non-front-fanged colubroid snakes: a current evidence-based analysis of medical significance. Toxicon. 2013; 69:103–113.

7. Ramos OH, Selistre-de-Araujo HS. Snake venom metalloproteases: structure and function of catalytic and disintegrin domains. Comp Biochem Physiol C Toxicol Pharmacol. 2006; 142:328–346.

8. Eble JA. Matrix biology meets toxinology. Matrix Biol. 2010; 29:239–247.

9. Larréché S, Mion G, Mayet A, Verret C, Puidupin M, Benois A, Petitjeans F, Libert N, Goyffon M. Antivenin remains effective against African Viperidae bites despite a delayed treatment. Am J Emerg Med. 2011; 29:155–161.

10. Escalante T, Rucavado A, Fox JW, Gutierrez JM. Key events in microvascular damage induced by snake venom hemorrhagic metalloproteinases. J Proteomics. 2011; 74:1781–1794.

11. Sajevic T, Leonardi A, Krizaj I. Haemostatically active proteins in snake venoms. Toxicon. 2011; 57:627–645.

12. Sohn YD, Hong SY, Cho KS, Choi WS, Song SW, Bae JS, Kim DS, Chung KH. Acute and repeated dose toxicity studies of recombinant saxatilin, a disintegrin from the Korean snake (Gloydius saxatilis). Toxicon. 2008; 51:406–417.

13. Li QB, Huang GW, Kinjoh K, Nakamura M, Kosugi T. Hematological studies on DIC-like findings observed in patients with snakebite in south China. Toxicon. 2001; 39:943–948.

14. Lavonas EJ, Ruha AM, Banner W, Bebarta V, Bernstein JN, Bush SP, Kerns WP 2nd, Richardson WH, Seifert SA, Tanen DA, Curry SC, Dart RC. Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011; 11:2.

15. Yoo CK, Kim YM, Park MY, Park MS, Park YD, Park KS. Determination of venom toxicity and standardization of venom and antivenin of Korean Agkistrodon spp. Korean J Vet Public Health. 1999; 23:135–142.

16. Lee BJ, Hong SI, Kim HS, Kim TH, Lee JH, Kim HJ, Ryu BY, Kim HK. Hematological features of coagulopathy and the efficacy of antivenin therapy for a Korean snakebite. J Korean Surg Soc. 2007; 72:18–26.

17. Warrell DA. Snake bite. Lancet. 2010; 375:77–88.

18. Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon. 2003; 41:541–557.

19. Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med. 1996; 27:321–326.

20. You KM, Kwon WY, Kwon TH, Shin JH, Lee HJ. Optimal dose of antivenin for asymptomatic or minor envenomation patient with Korean viperidae injuries. J Korean Soc Emerg Med. 2013; 24:420–427.

21. Kim DH, Choe SM, Oh YM, Oh JS, Kyong YY, Choi KH. Clinical significance of delayed re-evaluation in initial symptoms following snakebite injury. J Korean Soc Clin Toxicol. 2009; 7:97–104.

22. Park EJ, Yoon SK, Ahn JH, Choi SC, Kim GW, Min YG, Lee KJ, Jung HS, Jung YS. Systemic complications occurring after Korean venomous snake bite, with focus on hematologic and neurologic complications. J Korean Soc Clin Toxicol. 2009; 7:90–96.

23. Jin SC, Lee JW, Yang SJ, Joo MD, Choi WI. Consideration of factors associated with complications and systemic symptoms of snake bites. J Korean Soc Emerg Med. 2008; 19:686–696.

24. Jun DH, Lee DP, Choi WI. Initial assessment of the snakebites with local effects. J Korean Soc Emerg Med. 2004; 15:523–530.

25. Kim ES, Choi WJ. Clinical review of venomous snake bite. J Korean Surg Soc. 2000; 59:433–440.

26. Cho NS, Park J. A clinical analysis of snake bite injury. J Korean Soc Emerg Med. 1996; 7:405–414.

27. Jang IS, Lee JA, Kim SY, Hyun SC, Park SM, Park JS, Kim GT, Song HS. Clinical features in snake bite. J Korean Soc Emerg Med. 1996; 7:580–589.

28. Kim GN, Cho SW, Hwang JY. A clinical analysis on venomous snake bite in west-south area of Korea. J Korean Surg Soc. 1995; 48:824–831.

29. Scharman EJ, Noffsinger VD. Copperhead snakebites: clinical severity of local effects. Ann Emerg Med. 2001; 38:55–61.

30. Jeon JC, Lee DH, Kwon GY, Kim SJ. Relation of first aid associated with complications after snake bites. J Korean Soc Clin Toxicol. 2009; 7:105–112.

31. Toschlog EA, Bauer CR, Hall EL, Dart RC, Khatri V, Lavonas EJ. Surgical considerations in the management of pit viper snake envenomation. J Am Coll Surg. 2013; 217:726–735.

32. Bush SP. Snakebite suction devices don't remove venom: they just suck. Ann Emerg Med. 2004; 43:187–188.

33. Campbell BT, Corsi JM, Boneti C, Jackson RJ, Smith SD, Kokoska ER. Pediatric snakebites: lessons learned from 114 cases. J Pediatr Surg. 2008; 43:1338–1341.

34. Han SK, Kim IS, Ryu S, Lee JW, Kim SW, Yoo IS, You YH, Park JS, Min MG. The effectiveness of antivenin in treating snake bites resulting in minimal clinical symptoms. J Korean Soc Emerg Med. 2007; 18:577–583.

35. Hifumi T, Yamamoto A, Morokuma K, Okada I, Kiriu N, Ogasawara T, Hasegawa E, Kato H, Inoue J, Koido Y, Takahashi M. Clinical efficacy of antivenom and cepharanthine for the treatment of Mamushi (Gloydius blomhoffii) bites in tertiary care centers in Japan. Jpn J Infect Dis. 2013; 66:26–31.

36. Morokuma K, Kobori N, Fukuda T, Uchida T, Sakai A, Toriba M, Ohkuma K, Nakai K, Kurata T, Takahashi M. Experimental manufacture of equine antivenom against yamakagashi (Rhabdophis tigrinus). Jpn J Infect Dis. 2011; 64:397–402.

37. Girish KS, Kemparaju K. Overlooked issues of snakebite management: time for strategic approach. Curr Top Med Chem. 2011; 11:2494–2508.

38. Solano S, Segura A, Leon G, Gutierrez JM, Burnouf T. Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation. Biologicals. 2012; 40:129–133.

39. Otero-Patiño R, Segura A, Herrera M, Angulo Y, Leon G, Gutierrez JM, Barona J, Estrada S, Pereanez A, Quintana JC, Vargas LJ, Gomez JP, Diaz A, Suarez AM, Fernandez J, Ramirez P, Fabra P, Perea M, Fernandez D, Arroyo Y, Betancur D, Pupo L, Cordoba EA, Ramirez CE, Arrieta AB, Rivero A, Mosquera DC, Conrado NL, Ortiz R. Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia. Toxicon. 2012; 59:344–355.

40. Seong WK, Chung GT, Shin KS, Kim HH, Park KS, Oh HB. Immunological characterization of the venoms from Korean snakes of the genus Agkistrodon for therapeutic antivenin production. Korean J Vet Public Health. 1999; 23:21–31.

41. Gao JF, Wang J, Qu YF, Ma XM, Ji X. Immunoreactivity between venoms and commercial antiserums in four Chinese snakes and venom identification by species-specific antibody. J Immunol Methods. 2013; 387:211–218.

42. Ariaratnam CA, Meyer WP, Perera G, Eddleston M, Kuleratne SA, Attapattu W, Sheriff R, Richards AM, Theakston RD, Warrell DA. A new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell's viper (Daboia Russelii Russelii): a preliminary dose-finding and pharmacokinetic study. Am J Trop Med Hyg. 1999; 61:259–265.

43. Otero R, Leon G, Gutierrez JM, Rojas G, Toro MF, Barona J, Rodriguez V, Diaz A, Nunez V, Quintana JC, Ayala S, Mosquera D, Conrado LL, Fernandez D, Arroyo Y, Paniagua CA, Lopez M, Ospina CE, Alzate C, Fernandez J, Meza JJ, Silva JF, Ramirez P, Fabra PE, Ramirez E, Cordoba E, Arrieta AB, Warrell DA, Theakston RD. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg. 2006; 100:1173–1182.

44. Mion G, Ruttimann M, Saissy JM, Olive F. Efficacy of antivenom therapy (Bitis-Echis-Naja) in the treatment of bites by the carpet viper (Echis carinatus). Intensive Care Med. 1997; 23:Suppl 1. S179.

45. Brown SG, Caruso N, Borland ML, McCoubrie DL, Celenza A, Isbister GK. Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy. Intensive Care Med. 2009; 35:1532–1538.

46. Isbister GK, Buckley NA, Page CB, Scorgie FE, Lincz LF, Seldon M, Brown SG. ASP Investigators. A randomized controlled trial of fresh frozen plasma for treating venom-induced consumption coagulopathy in cases of Australian snakebite (ASP-18). J Thromb Haemost. 2013; 11:1310–1318.

47. Zengin S, Yilmaz M, Al B, Yildirim C, Yarbil P, Kilic H, Bozkurt S, Kose A, Bayraktaroglu Z. Plasma exchange as a complementary approach to snake bite treatment: an academic emergency department's experiences. Transfus Apher Sci. 2013; 03. 29. [Epub]. http://dx.doi.org/10.1016/j.transci.2013.03.006.

48. Klaewsongkram J. A role of snake antivenom skin test from the allergist's point of view. Acta Trop. 2009; 109:84–85.

49. Thiansookon A, Rojnuckarin P. Low incidence of early reactions to horse-derived F(ab')(2) antivenom for snakebites in Thailand. Acta Trop. 2008; 105:203–205.

50. Nuchpraryoon I, Garner P. Interventions for preventing reactions to snake antivenom. Cochrane Database Syst Rev. 2000; (2):CD002153.

51. Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom. Ann Emerg Med. 2008; 51:407–411.

52. Stone SF, Isbister GK, Shahmy S, Mohamed F, Abeysinghe C, Karunathilake H, Ariaratnam A, Jacoby-Alner TE, Cotterell CL, Brown SG. Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation. PLoS Negl Trop Dis. 2013; 7:e2326.

53. LoVecchio F, Klemens J, Roundy EB, Klemens A. Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ Med. 2003; 14:220–221.

54. Ko JH, Chung WH. Serum sickness. Lancet. 2013; 381:e1.

55. Lavonas EJ, Schaeffer TH, Kokko J, Mlynarchek SL, Bogdan GM. Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review. BMC Emerg Med. 2009; 9:13.

56. Ruha AM, Curry SC, Albrecht C, Riley B, Pizon A. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon. 2011; 57:53–59.

57. Bush SP, Seifert SA, Oakes J, Smith SD, Phan TH, Pearl SR, Reibling ET. Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients. Toxicon. 2013; 69:29–37.

58. Kim JJ, Lim YS, Lim HK, Kim JK, Hyun SY, Yang HJ, Lee G. A case report of snake bites during pregnancy. J Korean Soc Emerg Med. 2009; 20:223–226.

59. Lee JH, Ahn SM, Jung BY. Anticholinesterase treatment for patients with paralytic strabismus following a viper bite. J Korean Ophthalmol Soc. 2009; 50:1698–1704.